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Human Use Pharmaceuticals in the Estuarine Environment: 

A Survey of the Chesapeake Bay, Biscayne Bay and the Gulf of the 

Farallones 
Introduction 
The assessment of emerging risks in the aquatic 
environment is a major concern and focus of envi-
ronmental science (Daughton and Ternes, 1999).  
One signiﬁcant class of chemicals that has received 
relatively little attention until recently are the human 
use pharmaceuticals. 
In 2004, an estimated 2.6 billion prescriptions were 
curring in groundwater, typically as a result of their 
disposal in landﬁ lls (Jones et al., 2001). 
Halling-Sørensen et al. (1998) noted that pharma­
ceuticals are developed with the intention of having 
a biological effect, and often have physico/chemical 
properties (e.g., ability to pass through membranes, 
persistence) chosen to avoid their inactivation prior 
written for the top 300 pharmaceu­
ticals in the U.S. (RxList, 2005). 
Mellon et al. (2001) estimated that 1.4 
million kg of antimicrobials are used 
in human medicine every year.  The 
use of pharmaceuticals is also esti­
mated to be on par with agrochemicals
(Daughton and Ternes, 1999).  Unlike 
agrochemicals (e.g., pesticides) which 
tend to be delivered to the environ­
ment in seasonal pulses, pharmaceuti­
cals are continuously released through 
the use/excretion and disposal of these 
chemicals, which may produce the 
same exposure potential as truly per
sistent pollutants. 
Human use pharmaceuticals can enter 
the aquatic environment through a 
number of pathways, although the 
main one is thought to be via ingestion
and subsequent excretion by humans 
(Thomas and Hilton, 2004). Unused 
pharmaceuticals are typically ﬂushed 
down the drain or wind up in landﬁlls 
(Jones et al. 2001). 
o having a curative effect.  Brain 
t al. (2004) concluded that while 
he concentrations of individual 
ompounds in the environment are 
ow, the combination of a vari­
ty of pharmaceuticals in natural 
aters could prove toxicologically 
igniﬁcant. In addition, there is 
lso the possibility that pharma­
euticals could interact with other 
ollutant classes (e.g., pesticides 
r polycyclic aromatic hydrocar
ons (PAHs)) within the environ­
ent in unanticipated ways. 
In wastewater treatment plants (WWTPs), a num­
ber of pharmaceuticals are only partly removed by 
conventional biological treatments, resulting in their 
discharge to surface waters (Andreozzi et al., 2002). 
There have also been reports of pharmaceuticals oc-
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The effects of pharmaceuticals 
in the aquatic environment are 
just beginning to be investigated. 
Some pharmaceutical types such 
as lipid regulators or antidepres­
sants could, for example, interfere 
with an aquatic organism’s basic 
metabolism (e.g., energy transfer) 
or put it at a competitive disad­
vantage (e.g., behavioral effects).  
Boyd and Furlong (2002) noted that potential impacts 
of pharmaceuticals in the environment include abnor­
mal physiological effects, impaired reproduction, in­
creased cancer rates, and disruption of bacterial beds 
used to treat wastewater in many treatment plants. 
There is also concern that the continuous addition of 
antibiotics to the aquatic environment could result in 
1

the emergence of antibiotic-resistant, disease causing 
strains of bacteria (Yang and Carlson, 2004).  
Andreozzi et al. (2003) concluded that detection of 
pharmaceutical residues in the environment raises 
questions about the impacts they may be having, 
and highlighted the need for data on exposure in the 
aquatic environment. To assess exposure, informa­
tion is needed on the occurrence and concentration 
of these chemicals. One strategy is to ﬁrst look for 
pharmaceuticals in waters adjacent or downstream of 
likely points of discharge, such as WWTPs.  These 
areas would likely have higher concentrations of 
human use pharmaceuticals, and perhaps detectable 
impacts in aquatic organisms.  
Currently, the Environmental Protection Agency 
(EPA) and the U.S. Geological Survey (USGS) are 
investing signiﬁcant resources to assess the con­
tamination of freshwater systems with prescription 
and nonprescrip­
tion pharmaceu­
ticals (Daughton 
and Ternes, 1999; 
Kolpin, et al., 2002). 
To understand the 
implications in the 
coastal aquatic en­
vironment, NOAA’s 
National Status and 
Trends (NS&T) Pro­
gram, of the Center 
for Coastal Monitor­
ing and Assessment, 
conducted a pilot 
study to assess the presence of a suite of human use 
pharmaceuticals at selected sites in the Chesapeake 
Bay, Biscayne Bay, and the Gulf of the Farallones.  
The NS&T Program has monitored organic and 
inorganic contaminants and their effects in the 
Nation’s estuaries and coastal waters for over 20 
years (NOAA, 1998). As part of this effort, NS&T 
also investigates the occurrence of what have become 
known as “emerging contaminants of concern”, pre­
viously unknown or unidentiﬁed classes of contami­
nants that may be impacting the environment. Phar­
maceutical compounds fall within this category.  The 
goal of this pilot project was to assess the presence of 
a number of commonly prescribed human use phar­
maceuticals in three coastal areas of the U.S. 
Materials and Methods 
Water samples were collected in conjunction with 
three NOAA monitoring/research projects to as­
sess sediment contamination, macrobenthic infaunal 
communities, and bioeffects in the Chesapeake Bay, 
Biscayne Bay, and the Gulf of the Farallones.  The 
primary sampling area for the pharmaceuticals pilot 
project was the Chesapeake Bay.  All samples were 
collected in 2002. A description of sample collection 
and handling protocols follows. Ancillary data col­
lected at each site is shown in Table 1.     
Chesapeake Bay. Water samples from the Chesa­
peake Bay and tributaries were collected in Septem­
ber 2002. Sampling sites were primarily located ad­
jacent to WWTP outfalls.  The rationale for using this 
approach was to create 
the best opportunity for 
detecting the pharma­
ceuticals of interest. If 
there were no detec­
tions at these sites, it 
would be unlikely they 
would be detected in the 
estuarine environment 
in general. 
Water samples were col­
lected from the NOAA 
ship Ferrell, or from its 
launch in shallow water. 
Water samples were collected using a PVC Niskin­
type, 2 liter sampler rinsed with acetone and distilled 
water just prior to deployment. Composite (near 
surface and bottom) water samples were collected 
from 14 sites in the northern and southern portions 
of the Bay.  Water samples from the Niskin sampler 
were emptied into certiﬁed clean 4 liter amber glass 
jugs, and the samples were kept on ice until they were 
extracted at the University of Maryland, within two 
weeks of sample collection. 
Eight of the 14 sites sampled in the Chesapeake 
were adjacent to WWTPs, and included Back River, 
NOAA ship Ferrell used to collect water samples in the Chesa-
peake Bay. 
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Figure 1.  Sampling sites in the northern Chesapeake Bay (see Table 1 for site code descriptions).  
Patapsco River, Cox Point and Annapolis in the 
northern part of the Bay (Figure 1), and near the Vir
ginia Initiative, Atlantic, Chesapeake-Elizabeth, and 
Nansemond WWTPs in the southern portion (Figure 
2). Water samples taken at these sites were collected 
as close as possible to the point of discharge.  
For the Back River (BR) site, locating the exact 
discharge point for the WWTP was fairly straight­
forward, as the outfall is an above water concrete 
conduit. At the Patapsco River WWTP, even though 
the diffuser is on the bottom of the river at a depth 
of approximately 7 meters, the efﬂ uent plume was 
clearly visible on the surface of the water.  However, 
for the remaining ﬁ ve facilities sampled in the Chesa­
peake Bay, the point of discharge had to be estimated 
from latitude and longitude coordinates for the pipe, 
obtained from EPA’s online Permit and Compliance 
System (EPA, 2005) or from NOAA navigational 
charts. 
­
In addition to sampling adjacent to the WWTP dis­
charge points in the Back River and Patapsco River, 
water samples were also collected 1, 5, and 10 km 
(e.g., BR1, BR5, BR10) downstream of these WWTP 
facilities (Figure 1). The goal was to assess how dilu­
tion and other physical or biological processes might 
affect downstream concentrations of the pharmaceu­
ticals. 
Biscayne Bay. The second area sampled for this pilot 
project was Biscayne Bay.  Eleven sites in and around 
the western shore of the Bay were selected (Figure 
3 and Table 1).  Sampling sites were located at the 
mouth of drainage canals (e.g., Mowry Canal) or in 
areas further offshore where groundwater discharges 
to Biscayne Bay may be present.  Long et al. (1999) 
reported a number of sites in Biscayne Bay to be 
toxic to benthic infauna using one or more bioassays.   
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Jame
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Norfolk 
Virginia Beach # 
AST 
Figure 2.  Sampling sites in the southern Chesapeake Bay (see Table 1 for site code descriptions).  
All samples collected from Biscayne Bay were near-
surface water samples. Water samples were collected
by directly submerging a 4 liter certiﬁ ed clean amber 
jug beneath the surface of the water, capping the con­
tainer, and then placing it on ice in a cooler. 
As in the other locations for this study, the presence 
of human use pharmaceuticals could be used as an 
indicator of sewage-related inputs (WWTP or septic) 
and in Biscayne Bay, could conceivably be contrib­
uting to the observed sediment toxicity in the area 
(Long et al., 1999). 
Gulf of the Farallones. The ﬁ nal collection area for 
this pilot project was the Gulf of the Farallones in the
Paciﬁ c Ocean, off the coast of San Francisco (Figure 
4). As in the Chesapeake and Biscayne Bays, sam­
ples were taken in conjunction with a NOAA project 
 
 
to assess the presence of contaminants and toxicity to 
benthic infauna.  Samples were collected aboard the 
NOAA ship McArthur I. The ﬁ rst sample site (SF1) 
was 0.6 km north of the location of the outfall for 
the Oceanside WWTP, as reported in EPA’s online 
Permit and Compliance System (EPA, 2005) and as 
shown on the NOAA nautical chart.  The diffuser 
pipe is located approximately 6 km offshore at a 
depth of 24 meters. The second location was 0.6 km 
south of this location.  Composite (near surface and 
bottom) water samples were taken using a rosette-
type Niskin sampler at both sites. The water samples 
were emptied into certiﬁ ed clean 4 liter amber glass 
jugs, and kept on ice until they were ﬁ ltered and 
extracted at the University of Maryland. 
Sample Processing. All samples received were kept 
at  4oC, prior to ﬁ ltration and extraction.  The proto­
5
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Florida

Figure 3.  Sampling sites in Biscayne Bay (see Table 1 for site code descriptions).  
cols used for the extraction were those of Cahill et al. 
(2004). A brief description follows.  
Samples were ﬁrst ﬁ ltered through a 0.7 μm What-
man glass ﬁber ﬁ lter to remove particulate material.  
Each ﬁ ltered water sample received 1 μg/L of phen­
acetin-1-ethoxy 13C as a surrogate analyte.  One liter 
of the water sample was then passed through a condi­
tioned Waters® Oasis HLB SPE cartridge at a rate of 
15 ml/min. The cartridge was then eluted using 2 ml 
aliquots of methanol and acidiﬁ ed methanol.  
The methanol extracts were stored for an extended 
period of time (approximately 6 months) at -20oC 
at the University of Maryland prior to shipment to 
the U.S. Geological Survey (USGS) for analysis. 
Samples sent to the USGS were shipped overnight on 
dry ice. 
Sample Analysis. All sample analyses were carried 
out by the National Water Quality Laboratory of the 
USGS in Denver, Colorado.  Below is a summary of 
the analytical protocols provided by USGS (Werner, 
pers. comm. and Cahill et al., 2004). 
The sample methanol extracts were transferred to bo­
rosilicate glass test tubes, and 100 μl of reagent water 
was then added. The methanol was removed from the
samples using a Zymark® TurboVap sample concen­
trator with a water bath set at 40oC and nitrogen ﬂow 
at 5 PSI.  Samples were reduced to approximately 
100 μl ﬁ nal volume and reconstituted with 850 μl of 
formate buffer solution and 50 μl of an internal stan­
dard solution in methanol. 
The samples were analyzed by High-Performance 
Liquid Chromatography/Mass Spectroscopy (HPLC/ 
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San Francisco Bay 
Gulf of the Farallones San Francisco 
# SF1 
# SF2 
Figure 4.  Sampling sites in the Gulf of the Farallones (see Table 1 for site code descriptions).  
MS) using positive mode electrospray ionization 
(ESI) and selective ion monitoring to detect selected 
analytes. 
HPLC separation of analytes was achieved using a 
reverse-phase analytical column with a C18 stationary
phase. The chromatographic eluents used consisted 
of a 10 mM formate buffer in reagent water and 
acetonitrile. A multi-step gradient proﬁle was used to 
achieve an optimized separation of analytes. 
The HPLC column was coupled to a mass spectrome­
ter using ESI for detection and quantitation of indi­
vidual separated analytes.  ESI is used for these polar 
organic compounds because it will efﬁciently pro­
duce a charged ion (a protonated molecular ion) with 
relatively little fragmentation. This results in high 
 
sensitivity. To improve selectivity, the ESI source is 
operated so that in-source, collisionally-induced mo­
lecular dissociation occurs, producing characteristic 
patterns of fragment ions used to speciﬁcally identify 
the compound of interest.  Measured ratios of ion 
abundances of these fragments and of the molecular 
ions are used to either conﬁrm an analyte detection or 
to discount matrix interferences. 
Addition of the internal standard (D4 nicotinamide) 
immediately prior to analysis was used to correct for 
variations in ﬁnal extract volume when quantifying 
analyte results and calculating sample concentrations. 
Compounds Analyzed.  Selected properties of the 24 
human use pharmaceuticals and related compounds 
included in this pilot project, along with their molecu­
lar structures are shown in Table 2. The pharmaceuti­
7

 cals include a number of antibiotics, analgesics, lipid 
regulators and antidepressants. Selection of the com­
pounds was based on a variety of factors including 
number of prescriptions, persistence and the possibil­
ity of having an environmental impact, probability of 
being able to develop sensitive analytical protocols 
for water samples, and the availability of analytical 
standards. 
Twenty-one of the compounds in Table 2 (excluding 
caffeine, 1,7-dimethylxanthine, and cotinine)  are 
dispensed through a doctor’s prescription.  A number 
of the compounds such as caffeine and cotinine have 
been used as traditional markers of human sewage. 
Table 2 also includes a number of metabolites.  Dehy­
dronifedipine is a metabolite of the antianginal medi­
cation nifedipine. A metabolite of the antidepressant 
paroxetine was also 
included. Similarly, 
the presence of 1,7­
dimethylxanthine, a 
metabolite of caffeine 
was characterized as 
well. 
Of the human use 
pharmaceuticals 
listed in Table 2, 
eight (asterisked) 
were among the top 
100 prescribed medi­
cations, accounting 
for nearly 180 million 
prescriptions in the U.S. annually (RxList, 2005). 
Four antibiotics, including azithromycin, erythromy­
cin-H2O (erythromycin degradate), sulfamethoxazole, 
and trimethoprim were included. Erythromycin and 
azithromycin belong to a class of antibiotics known 
as macrolides, used to treat a wide variety of infec­
tions. In the U.S. in 2004, an estimated 2.5 million 
prescriptions were written for erythromycin, which 
is produced by Streptomyces erythraeus, a strain of 
ﬁlamentous bacteria. 
In this document, detections of erythromycin-H2O 
are reported rather than concentrations. Because of 
the low recovery levels of erythromycin-H2O from 
water samples (typically around 10%), and the pos­
sibility of interferences (similar ion fragments) from 
other sources (Furlong, pers. comm.), quantiﬁcation 
of erythromycin-H2O was not possible. 
Sulfamethoxazole belongs to another large group of 
antibiotics known as sulfonamides or sulfa medicines. 
Trimethoprim is a synthetic antibacterial.  Sulfa­
methoxazole and trimethoprim, often used in combi­
nation are especially effective in treating infections 
in urinary and digestive tracts, along with sinus and 
bronchial infections. There is concern regarding the 
possible overuse of antibiotics leading to increased 
antibiotic resistant, possibly pathogenic strains of 
bacteria, in humans and in the environment. 
Fluoxetine and 
paroxetine are two 
widely used anti­
depressants, both 
belonging to a class 
of compounds known 
as selective serotonin 
reuptake inhibitors. 
An estimated 35 
million prescriptions 
were written for these 
two pharmaceuticals 
in 2004 (RxList, 
2005). Low levels of 
serotonin have been 
linked to depression, 
and both ﬂuoxetine and paroxetine work to elevate 
levels of this neurotransmitter.  In addition, ﬂuox­
etine (Prozac®) also has a strong energizing effect, 
helping in the treatment of clinical depression cases 
involving a lack of energy.  Anxiety disorders can 
also lead to low levels of serotonin, needed to metab­
olize stress hormones, and ﬂuoxetine can be beneﬁ ­
cial by making more serotonin available. 
Paroxetine is also a widely prescribed selective sero­
tonin reuptake inhibitor. Recently, however, there has 
been concern regarding the use of these and other an­
tidepressants, related to possible increases in suicidal 
behavior.  
Launch from the NOAA ship Ferrell used to collect water samples 
from shallow areas.  
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Table 2. Selected properties of the pharmaceuticals analyzed. 
Compound Structure Use Brand/Common Name MW CAS 
1,7-dimethylxanthine Caffeine metabolite Paraxanthine 180.16 611-59-6 
*Acetaminophen Analgesic and antipyretic Tylenol® 151.17 103-90-2 
*Azithromycin Antibiotic Zithromax® 748.88 83905-01-5 
Caffeine Stimulant Caffeine 194.19 58-08-2 
Carbamazepine Antiepileptic, antidepressant Tegretol® 236.27 298-46-4 
Cimetidine Antacid Pepcid® 252.34 51481-61-9 
Codeine Analgesic Codeine 299.36 76-57-3 
Cotinine Nicotine metabolite Cotinine 176.22 486-56-6 
Dehydronifedipine 
Nifedipine (parent of dehydronifedipine) 
Antianginal Procardia® metabolite 344.32 67035-22-7 
Abbreviations: CAS, Chemical Abstract Service; MW, molecular weight; ®, Registered trademark 
*Top 100 prescribed pharmaceutical according to RxList (2005) 
9

Table 2. Selected properties of the pharmaceuticals analyzed (continued). 
Compound Structure Use Brand/Common Name MW CAS 
*Diltiazem Antianginal Cardizem® 450.98 33286-22-5 
Diphenhydramine Antihistamine Benadryl® 291.82 147-24-0 
Erythromycin-H2O Antibiotic E-mycin® 733.93 114-07-8 
*Fluoxetine Antidepressant Prozac® 345.8 54910-89-3 
Gemfibrozil Lipid regulator Lopid® 250.35 25812-30-0 
*Ibuprofen Analgesic and antipyretic Motrin® 351.83 15687-27-1 
*Metformin Antidiabetic Glucophage® 129.17 657-24-9 
Miconazole Antifungal Micatin® 416.12 22916-47-8 
Abbreviations: CAS, Chemical Abstract Service; MW, molecular weight; ®, Registered trademark 
*Top 100 prescribed pharmaceutical according to RxList (2005) 
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Table 2. Selected properties of the pharmaceuticals analyzed (continued). 
Compound Structure Use Brand/Common Name MW CAS 
*Paroxetine metabolite 
Paroxetine (parent compound) 
Antidepressant Paxil® metabolite - -
Ranitidine Antacid Zantac® 350.87 66357-35-5 
Salbutamol Antiasthmatic Proventil® 239.3 51022-70-9 
Sulfamethoxazole Antibiotic Bactrim® 253.28 723-46-6 
Thiabendazole Anthelmintic Mintezol® 201.26 148-79-8 
Trimethoprim Antibiotic Proloprim® 290.3 738-70-5 
*Warfarin Anticoagulant Coumadin® 308.33 129-06-6 
Abbreviations: CAS, Chemical Abstract Service; MW, molecular weight; ®, Registered trademark 
*Top 100 prescribed pharmaceutical according to RxList (2005) 
Two antianginal medications, diltiazem and a metab- muscle). Calcium channel blockers act to slow down 
olite of nifedipine, were included in the pilot project. the force of the contraction of the heart, lowering 
Approximately 12 million prescriptions were written blood pressure. 
for diltiazem and nifedipine in 2004 (RxList, 2005). 
Both drugs are known as calcium channel block- In 2004, approximately 6 million prescriptions were 
ers and are used in the treatment of hypertension, or written for the lipid regulator gemﬁ brozil (RxList, 
angina (chest pain due to a lack of oxygen to the heart 2005), used to lower triglycerides (fats) and cho­
11

lesterol in the blood. Gemﬁbrozil acts to increase 
the activity of the peroxisome proliferator-activated 
receptor-alpha, involved in the metabolism of fats and 
carbohydrates. Use of this pharmaceutical is thought 
to decrease the amount of fat produced by the liver.  
The antidiabetic drug metformin (over 25 million 
prescriptions in 2004) is used to treat type 2 (nonin­
sulin-dependant) diabetes. Insulin is a polypeptide 
hormone that helps regulate the metabolism of carbo­
hydrates. The mechanism of action of metformin is 
unclear, but it may reduce the rate of hepatic gluco­
neogenesis and also improve the peripheral uptake 
and utilization of glucose in the body.  Cimetidine 
belongs to a group of antacid medications known as 
H2-receptor antagonists, which block the action of 
histamine on the parietal cells of the stomach, de­
creasing the amount of acid produced by these cells. 
Carbamazepine is used in the treatment of epilepsy 
and sometimes for bipolar disorders. The mechanism 
of carbamazepine is not well understood, but appears 
to act primarily through inhibition of sodium chan­
nels, important in the process of muscle contraction 
and nerve impulse conduction. As will be seen, 
this compound appears to be fairly persistent in the 
aquatic environment. 
Finally, three analgesics, acetaminophen, ibuprofen 
and codeine were included. Analgesics or pain kill­
ers, are a diverse group of drugs. The term analge­
sic comes from the Greek term for “without pain”. 
Ibuprofen is a commonly prescribed pain medication 
(25 million prescriptions in the U.S.), and is also 
available as an over the counter medication in lower 
strengths. Ibuprofen is known as a COX-2 inhibitor.  
This class of pharmaceuticals selectively blocks the 
action of the COX-2 enzyme involved in the produc­
tion of prostaglandins, which have a role in pain and 
fever responses in the body.  Acetaminophen (16 
million U.S. prescriptions in 2004 and also available 
in over the counter preparations) is believed to reduce 
pain by reducing the production of prostaglandins. 
Codeine, the methylated form of morphine, is avail­
able in the U.S. by prescription. In the body, only 
about 10% of codeine is converted into morphine, 
producing a less potent effect than morphine itself.  
Codeine, like morphine, works directly on the central 
nervous system to relieve pain, and in particular at 
the synapses of the arcuate nucleus, located in the 
hypothalamus. 
Results and Discussion 
The results of the pharmaceutical analyses are shown 
in Table 3 (Chesapeake Bay) and Table 4 (Biscayne 
Bay and Gulf of the Farallones). Most often, chemi­
cals were below quantiﬁable detection; those that 
were detected were in the low ng/L range.  In the 
Chesapeake Bay, 13 of the 24 compounds (54%) 
analyzed were found at least once. In Biscayne Bay, 
only three compounds were detected; in the Gulf of 
the Farallones two were found. In their reconnais­
sance of wastewater contaminants in 139 streams 
in the U.S., the USGS detected 84% of these same 
pharmaceuticals (Kolpin et al., 2002). In Germany, 
Ternes (1998) detected over 80% of a variety of phar­
maceuticals in WWTP efﬂuents, and roughly 60% in 
surface waters. 
Chesapeake Bay. The primary study area for this 
pilot project was the Chesapeake Bay, which is also 
where most of the detections of the pharmaceuticals 
occurred. The four WWTPs in the northern part of the 
estuary (Figure 1) had a greater average number of 
detected compounds (6.5) per WWTP site compared 
to the southern Bay (1.7). One explanation for this 
is that the efﬂuent plumes from the WWTPs near 
Baltimore were typically more visible and therefore 
samples were known to be taken in proximity of the 
discharge.  In the southern part of the Chesapeake, 
there was no indication of the efﬂuent plume, and 
the location of the outfalls had to be estimated using 
latitude and longitude coordinates. At the Annapo­
lis sampling site in the northern part of the Bay, the 
efﬂuent plume was also not visible, and may have 
been one reason only two compounds were detected, 
similar to the number of detections at the WWTPs in 
the southern portion of the Bay. 
From Table 3, a number of patterns emerge. The most 
frequently detected pharmaceutical was carbamaze­
pine, found at all sites in the northern Bay, and at one 
site in the southern Bay. The maximum concentration 
of carbamazepine was 0.030 μg/L (Table 3) at the 
outfall of the Back River WWTP.  
12
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A number of other studies have also detected this 
pharmaceutical in surface waters. Boyd and Furlong 
(2002) found carbamazepine to be one of the most 
frequently detected pharmaceuticals in the Las Vegas
Wash, an urban river which drains the city of Las 
Vegas and empties into Lake Mead.  Ternes (1998) 
concluded this compound was ubiquitously present 
in rivers and streams in Germany.  In 2004, approxi­
mately 2.7 million prescriptions were written for 
carbamazepine in the U.S. (RxList, 2005). Yet, there
are many other compounds such as azithromycin (37 
million) and metformin (25 million) that were not 
detected, but have a far greater number of prescrip­
tions written. 
 
 
Studies have shown carbamazepine to be fairly 
persistent in the environment. Heberer (2002) found 
that less than 10% of 
carbamazepine is typi­
cally degraded during 
the sewage treatment 
process. Lam et al. 
(2004) calculated a 
mean half-life for car
bamazepine in outdoor 
ﬁeld microcosms of 82 
days, over four times 
higher than any of 
the other compounds 
(acetaminophen, 
atorvastatin, caffeine, 
levoﬂ oxacin, sertraline, 
sulfamethoxazole, and 

trimethoprim) in that study.  Andreozzi et al. (2003) 

calculated a half-life approaching 100 days for expo­

sures in northern latitudes. 

There has not been much work to date to assess the 

toxicity of carbamazepine to aquatic organisms.  The 

information generated to date appears to indicate 

that acute toxicity to a number of species of bacteria, 

green algae, diatoms, rotifers and a few crustaceans 

is on the order of mg/L, at least an order of magni­

tude higher than typical environmental concentra­

tions (Ferrari et al., 2004). A chronic toxicity study, 

however, indicated a 7-day no effect concentration on 

reproduction in the crustacean Ceriodaphnia dubia as 
low as 25 μg/L (Ferrari et al., 2004). Carbamazepine 
has a reported bioconcentration factor of approxi­
mately 15 (Jones et al., 2002) in daphnia, indicating 
it is not strongly accumulated from water column 
exposures in this organism.  
The antibiotic degradate erythromycin-H O was de­2
tected at 50% of the sites sampled in the Chesapeake 
Bay, including all those in the northern portion.  
In their assessment of pharmaceuticals and other 
organic contaminants in U.S. streams, Kolpin et al. 
(2002) found erythromycin-H O in over 21% of the 2
water samples taken, the second highest of any anti­
biotic included in their inventory.  Boyd and Furlong 
(2002) also found erythromycin in samples from the 
Las Vegas Wash, but not Lake Mead. Ashton et al. 
(2004) found erythromy­
cin in 44% of ﬁ nal WWTP 
efﬂuent samples, and 38% 
of downstream samples in 
the U.K. Erythromycin 
was below the limit of de­
tection in samples in ﬁve 
U.K. estuaries (Thomas 
and Hilton, 2004). 
There does not appear to 
be much data generated 
yet on the aquatic toxicity 
of erythromycin. Jones 
rd the NOAA ship Ferrell. et al. (2002) modeled a 
predicted environmental 
concentration (PEC of 0.81 μg/L), compared that 
with a predicted no effects concentration (PNEC) 
for ﬁsh and invertebrates, and calculated a PEC: 
PNEC ratio of 0.01. Ratios greater than one indicate 
the predicted environmental concentration would be 
above the no-effects concentration, and using this 
approach, would be cause for greater concern. Brain 
et al. (2004), found no signiﬁcant phytotoxicity in 
the duckweed Lemna gibba (EC50 > 1,000 μg/L). 
However, Jones et al. (2002) calculated a bioconcen­
tration factor for erythromycin of approximately 45, 
and suggested this pharmaceutical could accumulate, 
at least to some degree in aquatic biota. 
Collection of water samples aboa
­
15

In the Chesapeake Bay, dehydronifedipine, a me­
tabolite of the antianginal medication nifedipine, was 
found in ﬁve water samples, mainly from the Back 
River sites, at a maximum concentration of 0.003 μg/ 
L. In their study of U.S. streams, Kolpin et al. (2002) 
found dehydronifedipine in approximately 14% of 
the samples. Boyd and Furlong (2002) also found 
dehydronifedipine in water samples from the Las 
Vegas Wash, but not from Lake Mead. No informa­
tion was located on the aquatic toxicity of nifedipine 
or dehydronifedipine. 
The antibiotic trimethoprim was found twice (Pa­
tapsco River and Cox Creek) in the Chesapeake 
Bay samples, at a maximum concentration of 0.001 
μg/L. Ashton et al. (2004) detected trimethoprim 
in 65% of WWTP efﬂuent water samples, and 38% 
of downstream samples in ﬁve rivers in the U.K. In 
Germany, Hirsch et al. (1999) detected trimethoprim 
in approximately 90% of the WWTP efﬂ uents and 
20% of samples from streams and rivers. Kolpin et 
al. (2002) detected trimethoprim in 27% of samples 
from streams in the U.S., the highest of any antibiotic 
included in their study.  In microcosm experiments, 
Lam et al. (2004) calculated an average half-life of 
5.7 days. Brain et al. (2004) reported no signiﬁcant 
phytotoxicity in L. gibba. 
Sulfamethoxazole was detected at one sampling loca­
tion, Cox Creek, at a concentration of 0.011 μg/L. 
Kolpin et al. (2002) detected this antibiotic in 19% of 
stream samples. Boyd and Furlong (2002) detected 
sulfamethoxazole in both the Las Vegas Wash and in 
Lake Mead. In Germany, Hirsch et al. (1999) found 
this compound in all 10 WWTP efﬂ uents sampled, 
and in 50% of downstream samples. Ashton et al. 
(2004) detected sulfamethoxazole in 9% of WWTP 
efﬂuents, but it was undetectable downstream in the 
U.K. Thomas and Hilton (2004) did not detect this 
compound in U.K. estuaries. 
In their microcosm studies, Lam et al. (2004) found 
that sulfamethoxazole was one of the more persistent 
compounds tested, with a half-life of 19 days. In 
addition, Brain et al. (2004) found that sulfamethoxa­
zole was the most phytotoxic antibiotic tested, signiﬁ ­
cantly reducing the weight of L. gibba (EC50 of 81 
μg/L). 
The antianginal medication diltiazem was found 
twice in the Chesapeake Bay, with a maximum 
concentration of 0.003 μg/L. Kolpin et al. (2002) 
detected this pharmaceutical in approximately 14% of 
their water samples. Jones et al. (2002) calculated a 
PEC:PNEC of 0.34. 
Fluoxetine was detected once in the southern portion 
of the Chesapeake Bay at a concentration of 0.003 
μg/L. Kolpin et al. (2002) detected ﬂuoxetine in 1% 
of their samples. In Louisiana, Boyd et al. (2003) did 
not detect ﬂuoxetine in any surface water samples. 
Brooks et al. (2003) investigated the acute and sub­
lethal toxicity of ﬂuoxetine on a number of ﬁ sh and 
invertebrates, with the results indicating that effects 
concentrations were an order of magnitude higher 
than the highest reported municipal efﬂ uent concen­
tration. 
The analgesic acetaminophen was detected at the 
Patapsco River site at a concentration of 0.002 μg/L. 
Ibuprofen was not detected at any of the sites in the 
Chesapeake Bay, although it was detected in approxi­
mately 10% of the streams sampled by Kolpin et al. 
(2002). 
The pharmaceuticals detected in the Chesapeake Bay 
water samples (excluding caffeine and the caffeine 
metabolite 1,7-dimethylxanthine) are plotted by site 
in Figure 5. Carbamazepine was the most frequently 
detected pharmaceutical followed by the erythromy­
cin degradate, erythromycin-H2O. Cotinine, the me­
tabolite of the stimulant nicotine (commonly associ­
ated with tobacco), was detected in all water samples. 
Figure 5 also provides some evidence of a down­
stream (1, 5, and 10 km) gradient or transport. Car­
bamazepine, erythromycin-H2O and dehydronifdipine 
were detectable in water samples 10 km downstream 
of the Back River.  In the Patapsco River, a down­
stream gradient was not apparent. Interestingly, there 
was a detection of erythromycin-H2O at the 10 km 
Patapsco River, but not at the 1 or 5 km sites (Fig­
ure 5). The reason for this is unknown, but could be 
related to discharges from the Cox Creek WWTP, 
which had a detection of erythromycin-H2O, and is 
adjacent and somewhat upstream of the Patapsco 
River 10 km site (Figure 1). 
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Figure 5. Concentration of compounds detected (excluding caffeine) in Chesapeake Bay 
water samples. *Erythromcyin-H2O detected in these samples but not quantiﬁed. 
Biscayne Bay. Three compounds were detected at 
the sites in Biscayne Bay: cotinine, acetaminophen, 
and the anthelmintic thiabendazole. The maximum 
acetaminophen concentration (0.003 μg/L) in Bis­
cayne Bay (Table 4) was similar to that found at the 
Patapsco River site (Table 3). 
Fewer detections of pharmaceuticals at the Biscayne 
Bay sites compared with Chesapeake Bay is perhaps 
not surprising, as the sites in Biscayne Bay were not 
adjacent to WWTPs, but located near drainage canals 
which receive inputs from a variety of sources. There 
was speculation that sediment toxicity observed in an 
earlier study in Biscayne Bay (Cantillo and Lauen­
stein, 2004) could have been related to the presence 
of pharmaceuticals entering the Bay from wastewater 
or groundwater discharges. The results from this 
pilot project, however, would appear to make this less 
likely. 
Gulf of the Farallones. There were only two com­
pounds detected in the samples collected in the Gulf 
of the Farallones, cotinine (the metabolite of nico­
tine), and dehydronifedipine, a metabolite of the anti-
anginal medication nifedipine. The low detections in 
the Gulf of the Farallones site were likely due in part, 
to the difﬁculty in identifying the efﬂuent plume from 
the Oceanside WWTP, along with strong currents in 
the area. The diffuser heads are located 7 km off­
shore at a depth of 24 m. 
Comparison with Other Work. Table 5 contains 
published values for the detection of a number of the 
pharmaceuticals included in this study. In general, 
the concentrations found in the pilot project are some­
what lower than that reported elsewhere. The reason 
for this may be related to the amount of time that 
elapsed between the extraction of the water samples 
and the actual analysis, roughly 6 months. Although 
the extracts were kept at -20oC, it is likely that some 
17

Table 5.  Reported detections of selected human use pharmaceuticals in the aquatic environment. 
Compound Conditions Concentration      Frequency Reference 
(ug/l) (%) 
Carbamazepine WWTP effluent BDL 0 Weigel et al. (2004) 
Carbamazepine WWTP effluent BDL 0 Weigel et al. (2004) 
Carbamazepine WWTP effluent 0.3 - 1.03 NA Andreozzi et al. (2003) 
Carbamazepine surface waters 0.008-0.263 57-83 Kolpin et al. (2004) 
Carbamazepine surface waters 0.14 NA Boyd and Furlong (2002) 
Dehydronifedipine surface waters 0.0003-0.002 10 Kolpin et al. (2004) 
Dehydronifedipine surface waters 0.03 14 Kolpin et al. (2002) 
Diltiazem surface waters 0.002-0.106 20 Kolpin et al. (2004) 
Diltiazem surface waters 0.049 13 Kolpin et al. (2002) 
Fluoxetine surface waters BDL 0 Kolpin et al. (2004) 
Fluoxetine surface waters BDL 0 Boyd et al. (2003) 
Fluoxetine surface waters 0.012 1 Kolpin et al. (2002) 
Sulfamethoxazole WWTP effluent BDL - 0.09 NA Andreozzi et al. (2003) 
Sulfamethoxazole WWTP effluent 0.18 NA Yang and Carlson (2004) 
Sulfamethoxazole surface waters BDL-0.063 7 Kolpin et al. (2004) 
Sulfamethoxazole surface waters 0.07 (max.) NA Kolpin et al. (2004) 
Sulfamethoxazole surface waters 0.52 19 Kolpin et al. (2002) 
Trimethoprim WWTP effluent 0.66 (max.) NA Hirsch et al. (1999) 
Trimethoprim surface waters BDL-0.035 NA Kolpin et al. (2004) 
Trimethoprim surface waters BDL - 0.569 NA Thomas and Hilton (2004) 
Trimethoprim surface waters 0.042 (max.) 38 Ashton et al. (2004) 
Trimethoprim surface waters 0.30 NA Kolpin et al. (2002) 
Abbreviations: WWTP, wastewater treatment plant; BDL, below detection level; NA, not available; 
max., maximum  concentration detected; %, frequency of detection for the pharmaceutical 
degradation of the pharmaceuticals present in the 
extracts had taken place. As a result, the concentra­
tions reported for the Chesapeake Bay, Biscayne Bay, 
and the two sites in the Gulf of the Farallones, can be 
viewed as conservative estimates of the concentra­
tions originally present in the water samples. 
Summary and Conclusions 
The goal of this pilot project was to assess the pres­
ence of 24 human use pharmaceuticals and associated 
chemicals in selected estuarine and coastal waters. In 
the Chesapeake Bay, samples were collected adjacent 
to and downstream of wastewater treatment plants 
(WWTPs). In Biscayne Bay, samples were collected 
at the mouth of drainage canals and offshore areas 
that might be affected by inputs from the drainage 
canals or possibly groundwater discharges.  In the 
Gulf of the Farallones, two sites were sampled near 
the reported location of a WWTP outfall discharging 
to the Paciﬁc Ocean. 
Analysis of the Chesapeake water samples revealed 
the presence of 13 of the 24 compounds. In Biscayne 
Bay, three compounds were detected; in the Gulf of 
the Farallones, two were found. In the Chesapeake 
Bay on the Back River there was evidence of a down­
stream gradient; two pharmaceuticals (carbamazepine 
and erythromycin-H2O (erythromycin degradate)) 
were detected 1, 5, and 10 km downstream of the 
WWTP.  
The antiepileptic medication carbamazepine was 
detected in 11 of the 14 sites in the Chesapeake Bay. 
The published literature has documented the pres­
18

ence and persistence of carbamazepine in the aquatic 
environment. Erythromycin-H2O was detected, but 
not quantiﬁed at seven sites. Fewer detections of 
pharmaceuticals in Biscayne Bay was not surprising 
as none of the sites sampled were adjacent to WWTP 
outfalls. 
The effects of the pharmaceuticals in estuarine and 
coastal waters is currently unknown. An important 
ﬁrst step is to document which compounds are pres­
ent and in what concentrations, so that the appropri­
ate studies (laboratory and ﬁeld) can be designed to 
assess possible impacts. 
Future work, particularly in the Chesapeake Bay is 
recommended to assess pharmaceuticals in both the 
water column and sediments. In the Chesapeake Bay, 
the western shore has a higher human population, 
while the eastern shore is home to signiﬁ cant poul­
try CAFO (concentrated animal feeding operations) 
activity.  A study to assess the differences in the types 
(human versus animal use) and concentrations of 
pharmaceuticals present, and a concurrent assessment 
of antibiotic resistant populations of bacteria in both 
the western and eastern shores of the Chesapeake Bay 
would provide information needed to begin assessing 
the impacts (both human and environmental) of phar­
maceuticals in estuarine and coastal environments. 
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